SCHEMBL2904764

SCHEMBL2904764

C=[C]c1ccccc1N(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 4/20 0.40
GAA P10253 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KDM4E B2RXH2 2/20 0.39
CHEK1 O14757 1/20 0.39
NEK2 P51955 1/20 0.39
LIMK1 P53667 1/20 0.39
DYRK1A Q13627 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
HTR6 P50406 1/20 0.35
NSD2 O96028 1/20 0.35
EGFR P00533 1/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
EP300 Q09472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14142621 0.80 ALDH1A1 (0.43) MAPTALDH1A1GAATSHRTP53
SCHEMBL770158 0.80 MAPT (0.43) MAPTALDH1A1GAATSHRTP53
SCHEMBL148781 0.76 ALDH1A1 (0.55) MAPTALDH1A1GAATSHRTP53
SCHEMBL3763790 0.76 MAPT (0.40) MAPTALDH1A1GAATSHRTP53
SCHEMBL97296 0.76 ALDH1A1 (0.45) MAPTALDH1A1GAATSHRTP53
SCHEMBL1330188 0.76 ALDH1A1 (0.40) MAPTALDH1A1GAATSHRTP53
SCHEMBL9297384 0.76 TSHR (0.35) ALDH1A1TSHRLMNAMAPK1TDP1
Iodide SCHEMBL31276096 0.74 ALDH1A1 (0.53) MAPTALDH1A1GAATSHRTP53
SCHEMBL14565683 0.74 MAPT (0.39) MAPTALDH1A1GAATSHRTP53
SCHEMBL19810860 0.74 CHEK1 (0.52) MAPTALDH1A1GAATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1657239-B1 Chromene compound TOKUYAMA CORP (JP) 2010-08-11 EP disclosed
EP-1655293-B1 Chromene compound and articles comprising the same TOKUYAMA CORP (JP) 2010-03-31 EP disclosed
EP-1655294-B1 Chromene compound and articles comprising the same TOKUYAMA CORP (JP) 2010-03-24 EP disclosed
EP-1184379-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2009-11-18 EP disclosed
US-7521004-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2009-04-21 US disclosed
EP-1674460-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2009-01-21 EP disclosed
US-20070215844-A1 Chromene Compound TOKUYAMA CORPORATION (JP) 2007-09-20 US disclosed
EP-1674460-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2006-06-28 EP disclosed
EP-1657239-A2 Chromene compound Tokuyama Corporation (JP) 2006-05-17 EP disclosed
EP-1655293-A2 Chromene compound Tokuyama Corporation (JP) 2006-05-10 EP disclosed
EP-1655294-A2 Chromene compound Tokuyama Corporation (JP) 2006-05-10 EP disclosed
US-6723859-B2 BASE STRUCTURE IS A CHROMENE(3,2-A)FLUORENE RING CONTAINING SPIRO-FUSED RINGS; PHOTOCHROMIC LENSES; LARGE FADING RATE, LESS COLOR WHEN DETERIORATED, AND EXCELLENT LIGHT RESISTANCE IN THE PHOTOCHROMIC PROPERTIES TOKUYAMA CORPORATION (JP) 2004-04-20 US disclosed
US-20040014995-A1 Chromene compounds KAWABATA YUICHIRO (JP) 2004-01-22 US disclosed
US-20030096117-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2003-05-22 US disclosed
US-6469076-B1 Chromene compounds TOKUYAMA CORPORATION (JP) 2002-10-22 US disclosed
EP-1054010-B1 Chromene compound TOKUYAMA CORP (JP) 2002-07-24 EP disclosed
EP-1184379-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2002-03-06 EP disclosed
US-6340765-B1 PHOTOCHROMIC DYES AND DEVELOPMENT TOKUYAMA CORPORATION (JP) 2002-01-22 US disclosed
EP-1116723-A1 CHROMENE COMPOUNDS TOKUYAMA CORPORATION (JP) 2001-07-18 EP disclosed
EP-1054010-A1 Chromene compound TOKUYAMA CORPORATION (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014995-A1 Chromene compounds SMARCE1, SMARCB1, SMARCA2 MAPT 1285/4885ALDH1A1 2905/4885GAA 3387/4885
US-20070215844-A1 Chromene Compound CRY2, TYR, CRY1 MAPT 520/4885ALDH1A1 2110/4885GAA 4597/4885
US-20030096117-A1 Chromene compound SMARCE1, SMARCD2, SMARCB1 MAPT 1368/4885ALDH1A1 3101/4885GAA 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.